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Abstract
Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated for
single-agent use in the treatment of patients with multiple myeloma who have received at least 2
prior therapies and are progressing on their most recent therapy. Clinical investigations have been
completed or are under way to evaluate the safety and efficacy of bortezomib alone or in
combination with chemotherapy in multiple myeloma, both at relapse and presentation, as well as
in other cancer types. The antiproliferative, proapoptotic, antiangiogenic, and antitumor activities
of bortezomib result from proteasome inhibition and depend on the altered degradation of a host
of regulatory proteins. Exposure to bortezomib has been shown to stabilize p21, p27, and p53, as
well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κ B-α , which prevents
activation of nuclear factor κ B-induced cell survival pathways. Bortezomib also promoted the
activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum
stress response. The anticancer effects of bortezomib as a single agent have been demonstrated in
xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic,
head and neck, and colon cancer, and in melanoma. In these preclinical in vivo studies, bortezomib
treatment resulted in decreased tumor growth, angiogenesis, and metastasis, as well as increased
survival and tumor apoptosis. In several in vitro and/or in vivo cancer models, bortezomib has also
been shown to enhance the antitumor properties of several antineoplastic treatments. Importantly,
bortezomib was generally well tolerated and did not appear to produce additive toxicities when
combined with other therapies in the dosing regimens used in these preclinical in vivo investigations.
These findings provide a rationale for further clinical trials using bortezomib alone or in
combination regimens with chemotherapy, radiation therapy, immunotherapy, or novel agents in
patients with hematologic malignancies or solid tumors.
Introduction
Bortezomib (VELCADE®, formerly PS-341) was approved
for the treatment of patients with relapsed or refractory
multiple myeloma in May 2003 by the US Food and Drug
Administration [1] and in April 2004 by the Committee
for Proprietary Medicinal Products of the European
Union. A number of clinical studies evaluating the activity
and safety of bortezomib in multiple myeloma, as well as
in other types of cancer, have been conducted [2-10] or
are ongoing [11]. Therefore, a review of key preclinical
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studies that have explored the mechanisms of action and
provided the rationale for clinical investigation of this
novel agent in multiple myeloma and other cancer types
is warranted.
Mechanism of action
Bortezomib, a boronic acid dipeptide (Figure 1A) [12], is
a highly selective, reversible inhibitor of the 26S proteas-
ome that was first shown to exhibit antitumor properties
in a panel of 60 cancer cell lines from the US National
Cancer Institute [13]. The proteasome is an enzyme com-
plex that primarily functions in the degradation of mis-
folded proteins and is essential for the regulation of the
cell cycle. Proteasomes are localized in the nucleus and
cytosol, where they are largely associated with centro-
somes, the cytoskeleton, and the outer endoplasmic retic-
ulum [14]. Damaged intracellular proteins are targeted for
elimination by the proteasome through ubiquitination
(Figure 1B). Many of the substrates that have been identi-
fied are proteins that function in the regulation of tran-
scriptional activation, signal transduction, cell cycle
proliferation, and apoptosis (Figure 2, Table 1) [15-29].
Several independent investigators have found that borte-
zomib inhibits activation of the transcription factor
nuclear factor κ B (NF-κ B) [15-20,30]. NF-κ B is important
for cell survival and is activated in response to cell stress,
including that induced by cytotoxic agents, radiation, or
DNA damage. NF-κ B is overexpressed in several tumors
and regulates the expression of genes involved in apopto-
sis (including Bcl-2 and Bcl-xL), cell cycle progression,
inflammation, and angiogenesis (including interleukin
[IL]-6, IL-8, and vascular endothelial growth factor
[VEGF]) [31-33]. NF-κ B is normally bound in the cytosol
to inhibitor κ B-α  (Iκ Bα ). Phosphorylation, ubiquitina-
tion, and degradation of Iκ Bα  are required for NF-κ B to
translocate to the nucleus and activate the transcription of
target genes. Bortezomib blocks the activation of NF-κ B
by preventing proteasomal degradation of Iκ Bα . Through
inhibition of NF-κ B, bortezomib not only promotes
apoptosis of cancer cells but also sensitizes these cells to
chemotherapy [15,20,30], radiation [16], or immuno-
therapy [19]. However, because specific NF-κ B inhibition
alone via PS-1145 only partially inhibits proliferation of
tumor cells [18], the cytotoxic activity of bortezomib must
also depend on altered regulation of other signal trans-
duction pathway targets [18].
The intracellular levels of a number of other proteins that
regulate gene transcription, apoptosis, and proliferation
are significantly affected by bortezomib (Table 1). c-Jun-
NH2 terminal kinase (JNK) is a protein that promotes cell
death in response to stress and increased levels of mis-
folded proteins [34]. Bortezomib treatment leads to acti-
vation of JNK in multiple myeloma [21,22] and non-
small cell lung cancer cells [23]. These studies further
Chemical structure of the proteasome inhibitor bortezomib: pyrazylcarbonyl-Phe-Leu-boronate (A) Figure 1
Chemical structure of the proteasome inhibitor bortezomib: pyrazylcarbonyl-Phe-Leu-boronate (A). Schematic illustration of 
the ubiquitin-proteasome pathway. Misfolded proteins (e.g., p53) are targeted for degradation by the 26S proteasome via phos-
porylation and ubiquitination (B). Following substrate degradation, the ubiquitin tags and peptides are recycled for future use.Cancer Cell International 2005, 5:18 http://www.cancerci.com/content/5/1/18
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showed that specific inhibition of JNK activation, either
genetic or pharmacologic, prevented mitochondrial
release of cytochrome c and Smac, activation of caspase-8,
-9, and -3, and apoptosis.
Proteasome inhibition has also been shown to stabilize
the cyclin-dependent kinase inhibitors p21 and p27, the
tumor suppressor p53, and the proapoptotic proteins Bid
and Bax [15,21,23-27]. The increased levels of activated
p21, p27, p53, Bid, and Bax result in inhibition of cell
cycle progression and/or promotion of apoptosis in
response to bortezomib. Interestingly, sensitivity to pro-
teasome inhibition was partially dependent on the p53
status of breast [35] and lung cancer in vitro [36], but bort-
ezomib-induced apoptosis and/or chemosensitization
were p53 independent in prostate [13], multiple mye-
loma [15], and colon cancer cells [30]. Therefore, the
degree of variability in the sensitivity to bortezomib with
respect to p53 status appears cell-type dependent.
A recently published study found that bortezomib pre-
vented activation of caveolin-1 in multiple myeloma cells
[28]. Activation of caveolin-1, a protein that functions in
cell motility or migration in a number of tissues, requires
phosphorylation. In this report, bortezomib was shown to
prevent phosphorylation of caveolin-1 by VEGF, a proan-
giogenic cytokine and transcriptional target of NF-κ B [37].
Bortezomib also inhibited VEGF secretion by the bone
marrow. Together, these findings demonstrate important
Inhibition of the proteasome by bortezomib results in activation of JNK, stabilization of p53, Bid, Bax, p21, p27, caveolin-1, and  Iκ Bα , resulting in inhibition of NF-µB Figure 2
Inhibition of the proteasome by bortezomib results in activation of JNK, stabilization of p53, Bid, Bax, p21, p27, caveolin-1, and 
Iκ Bα , resulting in inhibition of NF-κ B. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, 
migration, and angiogenesis and promotion of apoptosis of cancer cells.Cancer Cell International 2005, 5:18 http://www.cancerci.com/content/5/1/18
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mechanisms by which bortezomib may inhibit migration
of cancer cells as well as tumor angiogenesis.
The specific proteins mentioned have all been shown to
be at least partially responsible in various models for the
antiproliferative, proapoptotic, antiangiogenic, and anti-
tumor effects of bortezomib. However, recent studies have
found that bortezomib results in cytotoxic activity
through activation of the endoplasmic reticulum stress
response [38-41]. The mechanism appears to involve
blockade of retrograde transportation and degradation of
damaged endoplasmic reticulum proteins by proteasome
inhibition [42]. Further studies are necessary to link these
new findings with the specific intracellular signals that
have been previously implicated in the anticancer activi-
ties of bortezomib.
Bortezomib alone
Bortezomib has shown promising antitumor activity in a
number of preclinical cancer murine models in vivo (Table
2) [13,17,19,24,30,43-49]. In a xenograft model of multi-
ple myeloma, bortezomib treatment resulted in signifi-
cant inhibition of tumor growth, an increase in overall
survival, and a decrease in tumor angiogenesis [43]. The
proteasome inhibitor was well tolerated up to 0.5 mg/kg
intravenously (IV) twice weekly for 4 weeks, with dose-
limiting toxicities, including weight loss, at 1 mg/kg. Two
recent reports evaluating the efficacy of bortezomib in
murine xenograft models of adult T-cell leukemia have
reached contradictory conclusions. Tan and Waldman
found that bortezomib treatment alone, 0.06 mg/kg intra-
peritoneally (IP), daily for 3 weeks, did not produce sig-
nificant antitumor effects [19]. However, a second group
reported that bortezomib 1.0 mg/kg IP twice weekly for 2
weeks resulted in antitumor activity [44]. Whereas Tan
and Waldman reported lethality at a more aggressive dos-
ing regimen of bortezomib 0.1 mg/kg IP twice daily for 2
weeks, slight, temporary weight loss was the only adverse
effect described by the second group of investigators [44].
It seems plausible that the discrepancy in activity and tox-
icity may be due to the differences in the doses and dosing
regimens. Based on the finding that proteasome inhibi-
tion by bortezomib lasts for up to 72 hours [8], more
recent preclinical studies have used twice-weekly, rather
than daily or twice-daily dosing, and have shown overall
greater activity with less toxicity.
An evaluation of the effects of bortezomib in murine
xenograft models of both lung and breast cancer was also
conducted [45]. Treatment with oral bortezomib 1.0 mg/
kg daily for 18 days caused tumor growth delays, as well
as a decrease in the number of metastases in the Lewis
lung cancer model. Furthermore, in a murine model, bort-
ezomib at a single IP dose of up to 5 mg/kg significantly
decreased the surviving fraction of breast tumor cells. A
decrease in the level of colony-forming-unit granulocyte
Table 1: Intracellular targets of bortezomib.
Protein Function Effect of bortezomib References
Iκ Bα Regulates the activity of the 
transcription factor, NF-κ B
Stabilization Hideshima et al [15], 2001
Russo et al [16], 2001
Sunwoo et al [17], 2001
Hideshima et al [18], 2002
Tan and Waldmann [19], 2002
Ma et al [20], 2003
JNK Phosphorylates and activates the 
transcription factor c-Jun
Activation Hideshima et al [21], 2003
Chauhan et al [22], 2004
Yang et al [23], 2004
p21, p27 CDK inhibitors Stabilization Shah et al [24], 2001
Hideshima et al [15], 2001
Yang et al [23], 2004
p53 Transcription factor and Tumor 
suppressor
Stabilization Williams and McConkey [25], 
2003
Hideshima et al [21], 2003
Yang et al [23], 2004
Bid Proapoptotic protein Stabilization Breitschopf et al [26], 2000
Bax Proapoptotic protein Stabilization Li and Dou [27], 2000
Caveolin-1 Promotes cell migration Inhibition of activation Podar et al [28], 2004
gp130 Cytokine signaling receptor Downregulation Hideshima et al [29], 2003
DNA-PKcs DNA repair Cleavage Hideshima et al [21], 2003
ATM DNA repair Cleavage Hideshima et al [21], 2003
Iκ Bα  = inhibitor κ B-α ; JNK = c-Jun-NH2 terminal kinase; CDK = cyclin-dependent kinase; DNA-PKcs = DNA protein kinase catalytic subunit; ATM 
= ataxia telangiectasia, mutated.Cancer Cell International 2005, 5:18 http://www.cancerci.com/content/5/1/18
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macrophages was the only toxicity noted in these
experiments.
Two groups of investigators have evaluated the efficacy of
bortezomib in murine xenograft models of prostate can-
cer. The first study concluded that bortezomib 1.0 mg/kg
IV weekly for 4 weeks reduced tumor growth by 60% [13].
The second study, in which bortezomib 1.0 mg/kg IV
every 72 hours for 15 days was administered, produced
similar results, with 50% and 80% inhibition in tumor
growth in two xenograft models [46]. This report further
showed that bortezomib significantly inhibited tumor
angiogenesis in one of the models, as measured by a
decrease in the number of CD31+ vessels in tumor sec-
tions. No toxicities were detected in either of these studies.
In a study of pancreatic cancer murine xenografts, treat-
ment with bortezomib 1.0 mg/kg IV or IP weekly for 4
weeks resulted in a 72% or 84% reduction in tumor
growth, as well as an increase in tumor cell apoptosis,
with no evidence of toxicity [24]. Another group found
that bortezomib 1.0 mg/kg IV biweekly for 2 to 3 weeks
significantly inhibited tumor growth and angiogenesis
and promoted apoptosis in 1 of 2 pancreatic cancer
xenograft murine models [47]. These investigators also
reported adverse events, including decreased body weight,
diarrhea, and gastrointestinal inflammation at doses
above 1.0 mg/kg and lethality at doses above 1.5 mg/kg.
Finally, bortezomib produced significant antitumor,
proapoptotic, and/or antiangiogenic effects in murine
xenograft models of head and neck [17] and colon cancer
[30], as well as melanoma [49]. Adverse events, including
dehydration, lethargy, weight loss, and death, were noted
at doses of 2.0 mg/kg IP 3 times weekly for 3 weeks in one
of these studies [17], whereas the other studies did not
report any toxicities at lower doses (Table 2).
These preclinical investigations have collectively demon-
strated the antitumor activity of bortezomib as a single
agent at tolerable levels in a variety of murine cancer mod-
els. However, because the standard approach to antineo-
plastic therapy generally involves the administration of
more than one agent or modality in an effort to prevent
the development of chemoresistance and increase tumor
cell kill, the effects of bortezomib in combination with
chemotherapy, radiation, immunotherapy, or novel
agents have been investigated in vitro and/or in vivo.
Combination therapy
A number of preclinical studies have evaluated the activity
of bortezomib in combination with other therapies (Table
3) [15,16,19,20,24,30,39,40,45,48-61]. The finding that
several cytotoxic agents as well as radiation [62,63] acti-
vate NF-κ B is a major rationale for combining proteasome
inhibitors with these therapies in the treatment of cancer.
Activated NF-κ B is free to translocate to the nucleus and
induce the expression of proinflammatory and antiapop-
totic genes, such as Bcl-2 and Bcl-xL, which promote
tumor cell survival [31-33]. Furthermore, inhibition of
NF-κ B has been implicated as an important mechanism
Table 2: Activity of bortezomib in tumor models in vivo.
Cancer Activity MTD References
Multiple myeloma Decreased tumor growth and 
angiogenesis; increased survival
0.5 mg/kg IV twice weekly for 4 
weeks
LeBlanc et al [43], 2002
Adult T-cell leukemia Decreased or no effect on tumor 
growth
1.0 mg/kg IP twice weekly for 2 
weeks
Tan and Waldmann [19], 2002
Satou et al [44], 2004
Lung Tumor growth delay and 
decreased lung metastases
1.0 mg/kg PO once daily for 18 
days
Teicher et al [45], 1999
Breast Decreased surviving fraction of 
tumor cells
5.0 mg/kg IP once Teicher et al [45], 1999
Prostate Decreased tumor growth; 
decrease or no effect on 
angiogenesis
1.0 mg/kg IV weekly for 4 weeks, 
or q 72 hrs for 15 days
Adams et al [13], 1999
Williams et al [46], 2003
Pancreatic Decreased or no effect on tumor 
growth and angiogenesis; increased 
or no effect on tumor apoptosis
1.0 mg/kg IV biweekly for 2 to 3 
weeks, or weekly for 4 weeks or 
0.25 mg/kg IP biweekly for 4 weeks
Shah et al [24], 2001
Nawrocki et al [47], 2002
Bold et al [48], 2001
Head and neck Decreased tumor growth and 
angiogenesis
1.5 mg/kg IP 3 times per week for 
3 weeks
Sunwoo et al [17], 2001
Colon Decreased tumor growth and 
increased tumor apoptosis
1.0 mg/kg IV twice weekly Cusack et al [30], 2001
Melanoma Decreased tumor growth and 
angiogenesis; increased tumor 
apoptosis
1.25 mg/kg SC twice weekly for 5 
weeks
Amiri et al [49], 2004
MTD = maximum tolerated dose; IV = intravenous; IP = intraperitoneal; PO = by mouth; SC = subcutaneous.Cancer Cell International 2005, 5:18 http://www.cancerci.com/content/5/1/18
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by which bortezomib sensitizes tumor cells to various
drugs or radiation [15,16,20,24,30,48-50,55,57,59,60].
Bortezomib with chemotherapy
In an investigation of lung cancer, bortezomib in combi-
nation with chemotherapeutic agents, including 5-fluor-
ouracil, cisplatin, paclitaxel, or doxorubicin, produced
additive antitumor and antimetastatic effects [45]. In this
same study, bortezomib also increased tumor-cell killing
by cyclophosphamide and cisplatin, as well as tumor-cell
killing by radiation, in an in vitro-in vivo model of breast
cancer. Although toxicity is difficult to assess in preclinical
models, no added toxicities were observed when
bortezomib was added to the other therapies, and borte-
zomib dose modifications were not required.
Several studies evaluating the effects of bortezomib in
combination with other therapies have been conducted in
multiple myeloma. These in vitro experiments collectively
confirmed that bortezomib enhanced the antiproliferative
and proapoptotic effects of conventional antimyeloma
agents, including melphalan, doxorubicin, and dexame-
thasone [15,20,50]. These investigators also reported that
multiple myeloma cell lines that were previously resistant
to melphalan, doxorubicin, dexamethasone, or mitox-
antrone were sensitized up to 1,000,000-fold by prior
exposure to subtoxic concentrations of bortezomib.
Finally, the researchers showed that bortezomib was not
only directly cytotoxic to the multiple myeloma cells but
that it also altered the microenvironment through inhibi-
tion of IL-6 to prevent the growth of tumor cells in prox-
imity to the bone marrow [15].
Two groups of researchers examined the effects of borte-
zomib in combination with the topoisomerase inhibitor
irinotecan in murine xenograft models of colon [30] and
pancreatic [24] cancer. Both these studies concluded that
combined inhibition of the proteasome and topoisomer-
ase resulted in enhanced antiproliferative and proapop-
totic effects. The combination of bortezomib and
irinotecan therapy further resulted in a 94% [30] or 89%
[24] decrease in tumor size compared with controls. These
tumors were also significantly smaller than those of the
mice receiving either bortezomib (26% or 65% decrease
in tumor size relative to controls) or irinotecan (48% or
43% decrease in tumor size relative to controls) as single
agents.
Xenograft models of pancreatic cancer were also used to
evaluate the activity of bortezomib in combination with
other standard chemotherapies [48,53]. Inhibition of the
proteasome increased the sensitivity of tumors to both
Table 3: Evaluation of bortezomib in combination with other therapies.
Type of therapy Drug or agent Cancer References
Chemotherapy 5-Fluorouracil, cisplatin, paclitaxel, 
doxorubicin, cyclophosphamide
Breast, lung Teicher et al [45], 1999
Melphalan, doxorubicin, 
dexamethasone
Multiple myeloma Hideshima et al [15], 2001
Mitsiades et al [50], 2003
Ma et al [20], 2003
Topoisomerase inhibitor: 
irinotecan
Colon Pancreatic Cusack et al [30], 2001
Shah et al [24], 2001
Gemcitabine Pancreatic Bladder Bold et al [48], 2001
Kamat et al [51], 2004
Pegylated liposomal doxorubicin Breast Small et al [52], 2004
Docetaxel Pancreatic Nawrocki et al [53], 2004
Temozolomide Melanoma Amiri et al [49], 2004
Radiation therapy Breast Colon Prostate Teicher et al [45], 1999
Russo et al [16], 2001
Pervan et al [54], 2001
Immunotherapy Daclizumab Adult T-cell leukemia Tan and Waldmann [19], 2002
Novel agents TRAIL/Apo2L Multiple myeloma, myeloid 
leukemia, renal
Mitsiades et al [55], 2001
Sayers et al [56], 2003
HSP90 inhibitor: 17-AAG Breast Mimnaugh et al [39], 2004
HDAC inhibitors: SAHA, sodium 
butyrate
CML, multiple myeloma, lung Denlinger et al [40], 2004
Yu et al [57], 2003
Mitsiades et al [58], 2004
Denlinger et al [59], 2004
Pei et al [60], 2004
Transplantation Allogeneic BMT Leukemia Sun et al [61], 2004
HSP = heat shock protein; HDAC = histone deacetylase; CML = chronic myelogenous leukemia; BMT = bone marrow transplantation.Cancer Cell International 2005, 5:18 http://www.cancerci.com/content/5/1/18
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gemcitabine [48] and docetaxel [53], because bortezomib
in combination with these agents resulted in significant
enhancement of antiproliferative, proapoptotic, antitu-
mor, and/or antiangiogenic activities.
The combination of bortezomib with temozolomide was
studied in models of malignant melanoma [49]. Borte-
zomib enhanced the antiproliferative and cytotoxic effects
of temozolomide in melanoma cells in vitro, and this
combined therapy produced complete remission of
tumors lasting more than 200 days in murine xenografts
in vivo. In contrast, tumors eventually progressed in mice
receiving either drug alone. Although specific toxicity
evaluations were not performed, no toxicities were
observed in any of these investigations.
Bortezomib with radiation, immunotherapy, or 
novel agents
A number of studies have reported on the radiosensitizing
properties of bortezomib. In addition to the previously
mentioned study in breast cancer [45], other laboratories
have demonstrated that bortezomib sensitizes colon [16]
and prostate [54] cancers to radiation-induced cytotoxic-
ity. In both clonogenic cell survival assays and murine
xenograft tumor models, pretreatment with bortezomib
enhanced the anticancer effects of irradiation with no
observed toxicity.
Another murine xenograft model was used to investigate
the effects of bortezomib in combination with daclizu-
mab, a humanized anti-IL-2Rα  antibody in adult T-cell
leukemia [19]. Although either agent alone resulted in
partial or no responses, bortezomib plus daclizumab
resulted in prolongation of the survival of tumor-bearing
mice. The only adverse effect of the combined therapy was
a slight temporary weight loss during the treatment
regimen.
Bortezomib has also demonstrated enhanced in vitro and/
or in vivo anticancer effects when combined with novel
agents such as TRAIL/Apo2L, a cell death-inducing ligand
[55,56], 17-N-allylamino-17-demethoxygeldanamycin
(17-AAG), an inhibitor of heat shock protein 90 [39], and
suberoylanilide hydroxamic acid (SAHA) or sodium
butyrate, both histone deactylase inhibitors
[40,57,59,60]. Pretreatment with bortezomib sensitized
multiple myeloma, myeloid leukemia, and renal cancer
cells but not normal B lymphocytes to TRAIL/Apo2L-
induced apoptosis [55,56]. In an in vivo experiment, bone
marrow and renal cancer cell mixtures, with or without
bortezomib and/or TRAIL/Apo2L, were transplanted into
the bone marrow of mice. Whereas all the mice receiving
cells treated with TRAIL/Apo2L died of leukemia within
35 days, 50% of those receiving cells treated with borte-
zomib and 90% of those receiving cells treated with both
TRAIL/Apo2L and bortezomib survived more than 100
days [56]. A mild transient thrombocytopenia was the
only toxicity observed in this study. Finally, while the
combination of bortezomib and 17-AAG, SAHA, or
sodium butyrate resulted in synergistic antiproliferative
and proapoptotic effects in vitro [39,40,57-60], these com-
binations have yet to be evaluated in tumor xenograft
models in vivo.
Sequence of administration
One of the areas of controversy has been the appropriate
timing of therapy with bortezomib in relation to other
antineoplastic agents. A brief discussion of some of the
conflicting results is warranted as these preclinical studies
may ultimately provide the rationale for clinical trials. In
vitro experiments conducted by Mitsiades and colleagues
revealed that optimal antimyeloma activity was achieved
when bortezomib was administered 24 hours after doxo-
rubicin [50]. The sequence of chemotherapy (gemcitab-
ine) followed by bortezomib was also found to be the
most effective in a model of pancreatic cancer [64]. In
contrast, Pei et al showed that bortezomib followed by a
second antineoplastic agent (SAHA) yielded the highest
level of apoptosis in a model of myeloma [60], and Mim-
naugh and colleagues found that maximal antiprolifera-
tive effects were observed upon simultaneous
administration of bortezomib and a heat shock protein 90
inhibitor in a model of breast cancer [39]. It is important
to note that these studies utilized bortezomib in combina-
tion with different antineoplastic agents in unique cancer
models. Further studies may elucidate the reasons for the
inconsistent findings.
Conclusion
The proteasome inhibitor bortezomib exhibits antiprolif-
erative, proapoptotic, antiangiogenic, and antitumor
activities in several cancer models. The mechanism of
action of bortezomib involves stabilization of NF-κ B,
p21, p27, p53, Bid, and Bax, inhibition of caveolin-1 acti-
vation, and activation of JNK as well as the endoplasmic
reticulum stress response. These preclinical evaluations
have found that bortezomib is well tolerated at doses that
demonstrated antitumor activity in xenograft models of
multiple myeloma, adult T-cell leukemia, cancer of the
lung, breast, prostate, pancreas, head and neck, and colon,
as well as melanoma. Bortezomib also enhances the anti-
cancer effects of chemotherapy, radiation therapy, immu-
notherapy, or novel agents, without added toxicities
requiring dose modifications. The studies provide a
rationale for clinical trials of bortezomib alone or in com-
bination with other therapies in patients with solid
tumors or hematologic malignancies.Cancer Cell International 2005, 5:18 http://www.cancerci.com/content/5/1/18
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